reports
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Loop Industries: Q3 results, set to move forward in India
This morning, Loop Industries published Q3 2024-25 (3-months ended Nov. 2024) results, aligned with expectations based on the company's current phase of deployment. Q3 2024-25 sales came in at USD52k (doubling YoY, vs. USD26k in Q3 2023-24) coming from ongoing contracts with customers. Although sup
Cartesian Therapeutics Highlights Progress and 2025 Strategic Prioriti...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia gravis; Safety profile continues to support outpatient administration based on updated data shared in December 2024 Phase 2 systemic lupus erythematosus (SLE) trial of Descartes-08 ongoing with expected data readout in 2H25 Cash resources expected to support pla...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324 shares of the Company’s common stock with an exercise price of $16.93, the closing trading price of the Company’s common stock on t...
- Jonathan Moreland
MMS MAXIMUS INC.
KVHI KVH INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
CULP CULP INC.
GTN GRAY TELEVISION INC.
PETS PETMED EXPRESS INC.
PLSE PULSE BIOSCIENCES
TDW TIDEWATER INC
QRTEA QURATE RETAIL INC. CLASS A
RZLT REZOLUTE
ARRY INC.
RCAT ARRAY TECHNOLOGIES
TKO RED CAT HLDGS INC
SUNS TKO GROUP HOLDINGS
SPGC INC.
SUNRISE REALTY TRUST
SPARTA SURGICAL CORP
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company’s common stock with an exercise price of $20.12, the closing trading price of the Company’s common stock on ...
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Loop Industries: factoring in EUR10m convertible and sale of first lic...
Loop Industries has announced the obtention of a EUR10m convertible financing from Reed Société Générale Group. Additionally, Loop has sold its first technology licence to a partnership (90% stake held by Reed Société Générale Group and 10% by Loop), thus unlocking a EUR10m upfront payment, expecte
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MYE MYERS INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
FCN FTI CONSULTING INC.
CVGI COMMERCIAL VEHICLE GROUP INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
MEDP MEDPACE HOLDINGS INC.
AUP AURINIA PHARMACEUTICALS INC.
CULP CULP INC.
PETS PETMED EXPRESS INC.
SCVL SHOE CARNIVAL INC.
TREE LENDINGTREE INC.
PMD PSYCHEMEDICS CORP.
DMLP DORCHESTER MINERALS L.P.
LILA LIBERTY LATIN AMERICA A
HHS HARTE-HANKS INC.
ETST EARTH SCIENCE TECH
TCPC BLACKROCK TCP CAPITAL CORP.
DBI DESIGNER BRANDS INC. CLASS A
ORGO ORGANOGENESIS HOLDINGS (A)
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
RZLT REZOLUTE
RVMD INC.
SSSS REVOLUTION MEDICINES
FTHM SUTTER ROCK CAPITAL CORP.
GNSS FATHOM HOLDINGS
CTGO GENASYS INC
AGL CONTANGO ORE INC.
NOTV AGILON HEALTH
AUID INC.
TRIN INOTIV
TCBX INC.
IBRX IPSIDY INC.
BIGZ TRINITY CAPITAL INC
MODD THIRD COAST BANCSHARES INC
GRNT IMMUNITYBIO INC
UAMY BLACKROCK INNOVATION AND GROWTH TST
TKO MODULAR MEDICAL INC
SRBK GRANITE RIDGE RESOURCES INC
NCDL U S ANTIMONY CORP
SPRU TKO GROUP HOLDINGS
AVDL INC.
CATX SR BANCORP INC
MRAI NUVEEN CHURCHILL DIRECT LENDING CORP
GWAV SPRUCE POWER HOLDING CORP
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
PERSPECTIVE THERAPEUTICS
INC.
MARPAI
INC.
GREENWAVE TECHNOLOGY SOLUTIONS INC
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Loop Industries: EUR10m financing and sale of first licence
Loop Industries has secured a EUR10m convertible financing from Reed Societe Generale Group. The convertible preferred financing features (i) a 13% PIK dividend rate, (ii) a 5-year term, and (iii) the option to convert to Loop common stock at USD4.75 per share or redeem in cash. As part of the deal
- Jonathan Moreland
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
CULP CULP INC.
NSC NORFOLK SOUTHERN CORPORATION
PMD PSYCHEMEDICS CORP.
DMLP DORCHESTER MINERALS L.P.
BBDC BARINGS BDC INC.
DBI DESIGNER BRANDS INC. CLASS A
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
RZLT REZOLUTE
CTGO INC.
NOTV CONTANGO ORE INC.
TRIN INOTIV
IBRX INC.
GRNT TRINITY CAPITAL INC
AVDL IMMUNITYBIO INC
MIO GRANITE RIDGE RESOURCES INC
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
Cartesian Therapeutics Announces Positive Updated Results from Phase 2...
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo Deepening responses observed over time in Phase 2b trial, with Descartes-08-treated participants observed to have a 5.5-point reduction in MG-ADL at Month 4 Durable responses observe...
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of ...
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company’s common stock with an exercise price of $19.11, the closing trading price of the Company’s common stock on the...
- Wedbush Research
GEO GEO GROUP INC. (THE)
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
TSLA TESLA INC
SAGE SAGE THERAPEUTICS INC.
RNG RINGCENTRAL INC. CLASS A
PZZA PAPA JOHN'S INTERNATIONAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
LOW LOWE'S COMPANIES INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
FTNT FORTINET INC.
EXPE EXPEDIA GROUP INC.
CXW CORECIVIC INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
PTGX PROTAGONIST THERAPEUTICS
RDFN REDFIN CORPORATION
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
HEAR TURTLE BEACH CORP.
RH RESTORATION HARDWARE INC.
PINS PINTEREST INC. CLASS A
GOSS GOSSAMER BIO
STOK STOKE THERAPEUTICS
DT DYNATRACE INC.
DDOG DATADOG INC CLASS A
APRE APREA THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
U UNITY SOFTWARE
RZLT REZOLUTE
ABNB AIRBNB INC. CLASS A
PLTR PALANTIR TECHNOLOGIES
VOR VOR BIOPHARMA
BUR BURFORD CAPITAL
CGEM CULLINAN ONCOLOGY INC
UPST UPSTART HOLDINGS
LBPH LONGBOARD PHARMACEUTICALS
VERA VERA THERAPEUTICS INC
TTD THE TRADE DESK
GLUE INC.
ARHS MONTE ROSA THERAPEUTICS INC
CCSI ARHAUS INC
RIVN CONSENSUS CLOUD SOLUTIONS INC
VIGL RIVIAN AUTOMOTIVE INC
PEPG VIGIL NEUROSCIENCE INC
TOST PEPGEN INC
EWTX TOAST INC
GETY EDGEWISE THERAPEUTICS INC
SKLZ GETTY IMAGES HOLDINGS INC
DNTH SKILLZ INC
CRBP DIANTHUS THERAPEUTICS INC
SYRE CORBUS PHARMACEUTICALS HOLDINGS INC.
SPYRE THERAPEUTICS INC.
- Dylan Shindler
- Laura Chico
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results an...
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 tr...
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH...
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that safety and tolerability data from patients treated with Descartes-08 will be featured during a poster presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego. A copy of the abstract is available...
- MarketLine Department
CoStar Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alli...
Summary Marketline's CoStar Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by CoStar Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investmen...
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Loop Industries: all eyes on India
This morning, Loop Industries published Q2 2024-25 (3-months ended Aug. 2024) results, aligned with expectations based on the company's current phase of deployment. Q2 2024-25 sales came in at USD23k (-57% YoY, vs. USD54k in Q2 2023-24) coming from ongoing contracts with customers. With revenues lo
Cartesian Therapeutics Announces Presentation of Results from Phase 2b...
Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the presentation of data from its Phase 2b trial of Descartes-08 in patients with generaliz...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company’s common stock with an exercise price of $17.11, the closing trading price of the Company’s common stock on...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.